CEL-SCI/CVM

$1.59

-2.45%
-
1D1W1MYTD1YMAX

About CEL-SCI

CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.

Ticker

CVM

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology & Drugs

CEO

Geert Kersten

Employees

43

Headquarters

Vienna, United States

CEL-SCI Metrics

BasicAdvanced
$87.99M
Market cap
-
P/E ratio
-$0.68
EPS
1.19
Beta
-
Dividend rate
$87.99M
1.19496
$3.23
$1.04
310.51K
1.264
0.782
74.846
89.291
-42.08%
-84.76%
-158.25%
-97.55%
6.445
7.06
19.98%

What the Analysts think about CEL-SCI

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 3 analysts.
432.7% upside
High $10.00
Low $7.00
$1.59
Current price
$8.47
Average price target

CEL-SCI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-
Net income
$-6.7M
-11.84%
Profit margin
0%
-

CEL-SCI Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 18.13%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.21
-$0.18
-$0.19
-$0.19
-
Expected
-$0.20
-$0.21
-$0.17
-$0.16
-$0.16
Surprise
5%
-14.29%
11.76%
18.12%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for CEL-SCI stock?

CEL-SCI (CVM) has a market cap of $87.99M as of April 16, 2024.

What is the P/E ratio for CEL-SCI stock?

The price to earnings (P/E) ratio for CEL-SCI (CVM) stock is 0 as of April 16, 2024.

Does CEL-SCI stock pay dividends?

No, CEL-SCI (CVM) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next CEL-SCI dividend payment date?

CEL-SCI (CVM) stock does not pay dividends to its shareholders.

What is the beta indicator for CEL-SCI?

CEL-SCI (CVM) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the CEL-SCI stock price target?

The target price for CEL-SCI (CVM) stock is $8.47, which is 432.7% above the current price of $1.59. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell CEL-SCI stock

Buy or sell CEL-SCI stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing